Allurion Technologies Inc. (ALUR)
NYSE: ALUR · IEX Real-Time Price · USD
1.750
-0.010 (-0.57%)
Mar 28, 2024, 4:00 PM EDT - Market closed
Company Description
Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight.
Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon) and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite.
The company is headquartered in Natick, Massachusetts.
Allurion Technologies Inc.
Country | United States |
Founded | 2009 |
Industry | Medical Devices |
Sector | Healthcare |
Employees | 268 |
CEO | Dr. Shantanu K. Gaur M.D. |
Contact Details
Address: 11 Huron Dr Ste 200 Natick, Massachusetts 01760 United States | |
Phone | 508-647-4000 |
Website | allurion.com |
Stock Details
Ticker Symbol | ALUR |
Exchange | NYSE |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001964979 |
ISIN Number | US02008G1022 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Dr. Shantanu K. Gaur M.D. | Co-Founder, Chief Executive Officer, President and Director |
Dr. Samuel G. Levy | Co-Founder |
Christopher Geberth | Chief Financial Officer and Treasurer |
Dr. Ram Chuttani M.D. | MD, Chief Medical Officer and Founding Partner |
Brendan Michael Gibbons | Chief Legal Officer and Corporate Secretary |
Matt Wright | Vice President of People |
Joyce Johnson | Senior Vice President of RA and QA |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 26, 2024 | 10-K | Annual Report |
Mar 21, 2024 | 424B3 | Prospectus |
Mar 21, 2024 | 424B3 | Prospectus |
Mar 21, 2024 | 8-K | Current Report |
Mar 15, 2024 | 8-K | Current Report |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Jan 8, 2024 | 8-K | Current Report |
Jan 2, 2024 | 424B3 | Prospectus |
Jan 2, 2024 | 424B3 | Prospectus |
Dec 29, 2023 | EFFECT | Notice of Effectiveness |